Show simple item record

dc.contributor.authorBenki-Nugent, Sarah F.
dc.contributor.authorMartopullo, Ira
dc.contributor.authorLaboso, Tony
dc.contributor.authorTamasha, Nancy
dc.contributor.authorWamalwa, Dalton C.
dc.contributor.authorTapia, Kenneth
dc.contributor.authorLangat, Agnes
dc.contributor.authorObimbo, Elizabeth Maleche
dc.contributor.authorMarra, Christina M.
dc.contributor.authorBangirana, Paul
dc.contributor.authorBoivin, Michael J.
dc.contributor.authorStewart, Grace C. John
dc.date.accessioned2022-02-10T19:56:36Z
dc.date.available2022-02-10T19:56:36Z
dc.date.issued2019
dc.identifier.citationBenki-Nugent, S. F., Martopullo, I., Laboso, T., Tamasha, N., Wamalwa, D. C., Tapia, K., ... & John-Stewart, G. C. (2019). High plasma soluble CD163 during infancy is a marker for neurocognitive outcomes in early treated HIV-infected children. Journal of acquired immune deficiency syndromes (1999), 81(1), 102.https://dx.doi.org/10.1097%2FQAI.0000000000001979en_US
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/2044
dc.description.abstractMonocyte activation may contribute to neuronal injury in aviremic HIV-infected adults; data are lacking in children. We examined the relation between monocyte activation markers and early and long-term neurodevelopmental outcomes in early-treated HIV-infected children.Prospective study of infant and child neurodevelopmental outcomes nested within a randomized clinical trial () and extended cohort study in Kenya.HIV-infected infants (N=67) initiated ART at age <5 months. Plasma soluble (s) CD163 (sCD163), sCD14 and neopterin were measured pre-ART (entry) and 6 months later. Milestone attainment was ascertained monthly during 24 months and neuropsychological tests (NPTs) were performed at 5.8–8.2 years post-initiation of ART (N=27). The relationship between neurodevelopment and sCD163, sCD14 and neopterin at entry and 6 months post-ART was assessed using Cox proportional hazards models and linear regression.Infants with high entry sCD163 had unexpected earlier attainment of supported sitting (5 vs 6 mo.; P=0.006) and supported walking (10 vs 12 mo.; P =0.02) with trends in adjusted analysis. Infants with high 6-month post-ART sCD163 attained speech later (17 vs 15 mo.; P=0.006; aHR, 0.47; P=0.02), threw toys later (18 vs 17 mo.; P =0.01; aHR, 0.53; P =0.04), and at median 6.8 years post-ART, had worse NPT scores (adj. mean z-score differences, cognition, −0.42; P =0.07; short-term memory, −0.52; P =0.08; nonverbal test performance, −0.39, P =0.05).Prior to ART, monocyte activation may reflect transient neuroprotective mechanisms in infants. Following ART and viral suppression, monocyte activation may predict worse short- and long-term neurodevelopment outcomes.en_US
dc.language.isoenen_US
dc.publisherJournal of acquired immune deficiency syndromesen_US
dc.subjectmonocyte, neurocognitive, antiretroviral, perinatal HIV, CD163, neurodevelopmenten_US
dc.titleHigh Plasma Soluble CD163 During Infancy Is a Marker for Neurocognitive Outcomes in Early-Treated HIV-Infected Childrenen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record